BRAF and neoplasm: Several clinicopathological characteristics, including age at diagnosis, tumor location, and patient survival, differ between patients with MLH1-deficient/BRAF-V600E–mutated dMMR CRC and those with MLH1-deficient/BRAF wild-type dMMR CRC (70, 71).